Skip to main content

Significant investments

Typically, building a strategic position begins by investing in a private company with development potential and expands at follow-on financing rounds as well as IPOs.

HBM Healthcare is committed to broad diversification according to the following parameters: private and public companies; development phase; therapeutic area; geography; company size (market capitalisation, valuation). Without the Board of Directors' approval, the acquisition value of an investment may not exceed 10 percent of net assets.

Overview as at 31 December 2018

Cathay Industrial Biotech
CHF
90
million
CHF
56
million
Y-mAbs Therapeutics
CHF
42
million
Vectura Group
Pacira Pharmaceuticals
CHF
40
million
Harmony Biosciences
CHF
32
million
CHF
26
million
Galapagos
Principia Biopharma
CHF
22
million